BCG in the Immunotherapy of Non-Hodgkin’s Malignant Lymphomas:Preliminary Results of a Controlled Trial
In a previous paper, we presented our current results of a randomized trial of the efficacy of BCG to maintain complete remission in patients with malignant lymphoma in whom complete remission had previously been induced by an association of chemo- and radiotherapy . There was a significant difference in the duration of complete remission in favor of patients treated with BCG scarifications as compared with the control group; this difference was about the same for patients with Hodgkin’s disease (who constituted two-thirds of the patients) and for the other patients suffering from non-Hodgkin’s lymphoma. We have concluded that BCG may be useful in maintaining complete remission and that a 3-year treatment seems sufficient. After obtaining these results, we continued this trial for non-Hodgkin’s lymphomas, and we present here the current results of this study.
KeywordsComplete Remission Malignant Lymphoma Anaplastic Carcinoma Leukemic Transformation High Grade Malignancy
Unable to display preview. Download preview PDF.
- 1.Chauvergne, J., Durand, M., Hœrni, B., Hœrni-Simon, G., Brunet, R., Lagarde, C.: Induction chemotherapy of non-Hodgkin’s malignant lymphomas. Eur. J. Cancer, 73, 399–400 (1977)Google Scholar
- 4.Lennert, K., Stein, H., Kaiserling, E.: Cytological and functional criteria for the classification of malignant lymphomas. Br. J. Cancer, 31, Suppl. II, 29–43 (1975)Google Scholar
- 5.Mathé, G., Amiel, J. L., Schwarzenberg, L. et al.: Les diverses approches immunologiques du traitement des cancers humains, XXXVIIe Congr. Fr. Med., Paris, Masson pub. 1969Google Scholar
- 7.Rosenberg, S. A.: Report of the committee on the staging of Hodgkin’s disease. Cancer Res., 26,1310 (1966)Google Scholar